Mitochondrial complex III quinone-binding sites (CIII Q-sites)

Mitochondrial complex III quinone-binding sites, specifically the Qo (outer) and Qi (inner) sites, are critical catalytic centers within the cytochrome bc1 complex (EC 1.10.2.2) of the electron transport chain (Wikipedia, NIH). These sites facilitate the Q-cycle, a process that couples the transfer of electrons from ubiquinol to cytochrome c with the translocation of protons across the inner mitochondrial membrane to generate a proton motive force for ATP synthesis (NIH, Journal of Biological Chemistry). The Qo site is also a significant source of mitochondrial reactive oxygen species (ROS), which play roles in cellular signaling, such as the stabilization of hypoxia-inducible factor 1-alpha (HIF-1α) during hypoxia (NIH, Nature). Pharmacological targeting of these sites is a well-established strategy in the development of antiprotozoal, antifungal, and antibacterial agents, such as atovaquone and strobilurins, which exploit structural differences between host and pathogen complexes (ResearchGate, MDPI). However, therapeutic use in humans is often limited by potential cytotoxicity and the rapid emergence of resistance through mutations in the mitochondrial-encoded cytochrome b subunit, such as the G143A mutation (NIH, MDPI). Genetic deficiencies in these sites or the complex as a whole lead to severe multisystem disorders characterized by exercise intolerance, lactic acidosis, and organ failure (MedlinePlus, NIH). In cancer research, the Qo site is investigated for its role in ROS-mediated tumor progression and as a potential target for modulating the hypoxic response (NIH). Overall, these sites represent a fundamental bioenergetic junction with significant implications for metabolic health, infectious disease treatment, and cellular stress responses (NIH).

Other names

Cytochrome bc1 complex quinone-binding sitesUbiquinol-cytochrome c reductase quinone-binding sitesQo and Qi sitesQP and QN sitesComplex III Q-sitesCytochrome b quinone-binding sites

Inhibition of the Q-cycle by blocking ubiquinol oxidation at the Qo site or ubiquinone reduction at the Qi site, thereby disrupting the mitochondrial proton gradient and ATP synthesis.